Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.32 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9237355 | 0.87 | PLA2G2C (0.37) | PLA2G2CLPAR1LPAR3CA1CA2 | |
| SCHEMBL22778250 | 0.86 | LPAR1 (0.43) | PLA2G2CLPAR1LPAR3CA1CA2 | |
| SCHEMBL22778183 | 0.85 | LPAR1 (0.45) | PLA2G2CLPAR1LPAR3P2RY10 | |
| SCHEMBL22778166 | 0.83 | LPAR1 (0.38) | PLA2G2CLPAR1LPAR3CA1CA2 | |
| SCHEMBL22778213 | 0.81 | PLA2G2A (0.38) | LPAR1LPAR3CA1CA2CA7 | |
| SCHEMBL23130705 | 0.81 | P2RY10 (0.45) | P2RY10 | |
| SCHEMBL28528617 | 0.81 | CA1 (0.38) | LPAR1LPAR3CA1CA2CA7 | |
| SCHEMBL28206699 | 0.81 | LPAR3 (0.46) | LPAR1LPAR3CA1CA2CA7 | |
| SCHEMBL28002680 | 0.81 | LPAR3 (0.46) | LPAR1LPAR3CA1CA2CA7 | |
| Methyl Alcohol SCHEMBL28536635 | 0.78 | LPAR3 (0.48) | LPAR1LPAR3CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| CN-114286671-A | Compositions and methods for biological delivery vehicles | DNALite治疗学公司 | 2022-04-05 | — | — | CN | claimed |
| US-10961197-B2 | Metal chelators for imaging, therapeutics, and bioanalysis | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-30 | — | — | US | claimed |
| WO-2020252375-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | claimed |
| EP-1771206-B1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2018-04-11 | — | — | EP | claimed |
| US-9486538-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2016-11-08 | — | — | US | claimed |
| EP-2992875-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | Silence Therapeutics GmbH (DE) | 2016-03-09 | — | — | EP | claimed |
| CN-102940891-B | Lipid, lipid complex and application thereof | SILENCE THERAPEUTICS AG (DE) | 2016-02-24 | — | — | CN | claimed |
| US-20150359906-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2015-12-17 | — | — | US | claimed |
| EP-1830888-B1 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS GMBH (DE) | 2015-08-05 | — | — | EP | claimed |
| US-8852472-B2 | Coated lipid complexes and their use | SILENCE THERAPEUTICS GMBH (DE) | 2014-10-07 | — | — | US | claimed |
| US-8357722-B2 | Lipids, lipid complexes and use thereof | Silence Therpeutics AG (DE) | 2013-01-22 | — | — | US | claimed |
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2012-03-15 | — | — | US | claimed |
| US-20100062967-A1 | COATED LIPID COMPLEXES AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2010-03-11 | — | — | US | claimed |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | SILENCE THERAPEUTICS AG (DE) | 2008-11-06 | — | — | US | claimed |
| JP-2007536324-A | — | — | 2007-12-13 | — | — | JP | claimed |
| EP-1771206-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | atugen AG (DE) | 2007-04-11 | — | — | EP | claimed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | claimed |
| EP-3500671-B1 | METHOD OF SELECTING TARGET SEQUENCES FOR THE DESIGN OF GUIDE RNAS | BROAD INST INC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, SGMS1 | PLA2G2C 470/4885LPAR1 34/4885LPAR3 39/4885 |
| US-20100062967-A1 | COATED LIPID COMPLEXES AND THEIR USE | HDLBP, NR1H3, CETP | PLA2G2C 326/4885LPAR1 69/4885LPAR3 108/4885 |
| US-20150359906-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | PLA2G2C 245/4885LPAR1 41/4885LPAR3 44/4885 |
| US-10961197-B2 | Metal chelators for imaging, therapeutics, and bioanalysis | TBCA, SLC39A3, TBL3 | PLA2G2C 3285/4885LPAR1 4015/4885LPAR3 3211/4885 |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | MGLL, LIPA, SGMS1 | PLA2G2C 523/4885LPAR1 32/4885LPAR3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.